Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine Combined With Ruxolitinib in Higher-risk MDS/MPN
NCT05817955Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Complete Response Rate at Cycle 6, Overall Survival at 2 years and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
03
Conditions
myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT05817955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05817955.